Skip to main content

Betarezeptorenblocker

  • Chapter
Arzneiverordnungs-Report 2017

Zusammenfassung

Betarezeptorenblocker hemmen die Funktion des sympathischen Nervensystems in allen Organen, die mit adrenergen Betarezeptoren (β1-/β2-) ausgestattet sind. Dazu gehören insbesondere das Herz, die Nieren und die glatte Muskulatur von Bronchien und Muskelgefäßen. Therapeutisch bedeutsam sind die Senkung der Herzfrequenz, des kardialen Sauerstoffverbrauchs, der Reninausschüttung aus der Niere und die Erniedrigung des Augeninnendrucks (Kapitel 38).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Aursnes I, Osnes J-B, Tvede IF, Gasemyr J, Natvig B (2007): Does atenolol differ from other ß-adrenergic blockers? BMC Clin Pharmacol 7:4

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2009): 23. Arterielle Hypertonie: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, Neu-Isenburg: S 597–628

    Google Scholar 

  • Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013): Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168: 3572–3579

    Google Scholar 

  • Beevers DG (2005): The end of beta blockers for uncomplicated hypertension? Lancet 366: 1510–1512

    Google Scholar 

  • Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38: 199–204

    Google Scholar 

  • Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013): Benefits of β blockers in patients with heart failure and reduced ejection fraction: network metaanalysis. BMJ 346: f596

    Google Scholar 

  • Chobanian AV, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute;. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). JAMA 289: 2560–72. Erratum in: JAMA 2003, 920:197

    Google Scholar 

  • CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13

    Google Scholar 

  • Deutsche Gesellschaft für Kardiologie – Deutsche Hochdruckliga – European Society of Cardiology – European Society of Hypertension (2013): Leitlinien für das Mangement der arteriellen Hypertonie: www.escardio/org-guidelines, www.dgk.org, www.hochdruckliga.de; Europ Heart J 2013: 34:2159-2219; https://doi.org/10.1093/euroheartj/eht151

  • DiNIcolantonio JJ, Fares H, Niazi AK, et al. (2015): ß-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 21(1): e000230

    Google Scholar 

  • Du Q, Sun Y, Ding N, Lu L, Chen Y (2014): Beta-blockers reducde the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PloS One 26:e113048. Doi: 10.1371/journalpone.o113048.eCollection2014

  • Eschenhagen T, Erdmann E (2010): 16. Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie – Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 229–243

    Google Scholar 

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcopd.org

  • Grundt C, Meier K, Grundt A, Lemmer B (2007): Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001–1007

    Google Scholar 

  • Hines KL, Peebles RS (2017): Management of the asthma-COPD overlap syndrome (AOCS): a review of the evidence. Curr Allergy Asthma Rep 17: 15, doi: 10.007/s11882-017-064

    Google Scholar 

  • Hohlfeld T, Kelm M (2010): 17. Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie – Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 245–257

    Google Scholar 

  • Hoppe UC, Erdmann E (2010): Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35: 535–541

    Google Scholar 

  • Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014): Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223-230

    Google Scholar 

  • Kreutz R, Kolloch R (2010): Arterielle Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 197–218

    Google Scholar 

  • Léauté-Labrèze C, Hoeger P, Mazereew-Hautier J, et al. (2015): A randomized, controlled trial of propranolol in infantile hemangioma. N Eng J Med 19:735-746

    Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553

    Google Scholar 

  • MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007

    Google Scholar 

  • Moen MD, Wagstaff AJ (2006): Nebivolol – a review of its use in the management of hypertension and chronic heart failure. Drugs 66: 1389–1409

    Google Scholar 

  • National Institute for Health and Care Excellence (NICE) (2011): Hypertension – Clinical management of primary hypertension in adults. Issued: August 2011. NICE clinical guideline 127: Internet: guidance.nice.org.uk/cg127

    Google Scholar 

  • Nationale VersorgungsLeitlinie (2013): Chronische Herzinsuffizienz. http://www.leitlinien.de/nvl/herzinsuffizienz

  • Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658

    Google Scholar 

  • POISE Study Group (2008): Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371: 1839–1847

    Google Scholar 

  • Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28 (11 Suppl 1): I19–27

    Google Scholar 

  • Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006

    Google Scholar 

  • Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511–514

    Google Scholar 

  • Wiysonge CS, Bradley HA, JV, Mayosi MB, Mbewu A, Opie LH (2012): Beta-blockers for hypertension. Cochrane Database Syst Rev. Nov 14: CD002003

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Björn Lemmer .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Lemmer, B. (2017). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54630-7_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54629-1

  • Online ISBN: 978-3-662-54630-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics